Halozyme Therapeutics, Inc. $HALO Shares Sold by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 167,544 shares of the biopharmaceutical company’s stock after selling 18,831 shares during the quarter. Kornitzer Capital Management Inc. KS owned 0.15% of Halozyme Therapeutics worth $18,497,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Bank of America Corp DE bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at $214,504,000. William Blair Investment Management LLC bought a new position in shares of Halozyme Therapeutics in the second quarter valued at $196,540,000. Jupiter Topco LLC bought a new position in shares of Halozyme Therapeutics in the second quarter valued at $105,570,000. Caisse de depot et placement du Quebec acquired a new position in shares of Halozyme Therapeutics during the second quarter valued at about $83,940,000. Finally, Congress Asset Management Co. grew its holdings in shares of Halozyme Therapeutics by 85.6% during the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after buying an additional 1,052,509 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $103.63 on Friday. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a market cap of $11.76 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 0.39 and a beta of 0.92. The stock’s fifty day simple moving average is $115.19 and its two-hundred day simple moving average is $84.73. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $134.00.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 488.26%. The firm had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. During the same quarter in the prior year, the business posted $1.72 EPS. The business’s revenue was up 39.1% compared to the same quarter last year. As a group, analysts forecast that Halozyme Therapeutics, Inc. will post 8.32 EPS for the current fiscal year.

Analysts Set New Price Targets

HALO has been the subject of several recent research reports. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. HC Wainwright raised their price target on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, Zacks Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $106.09.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $82,482,605.40. This represents a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 125,852 shares of company stock worth $13,538,046. 2.50% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion.

Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners.